AEGiS-GMHC: TREATMENT BRIEFS: 3TC Access Program

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

TREATMENT BRIEFS: 3TC Access Program

Gay Men's Health Crisis: Treatment Issues, Volume 8 no. 3 - May, 1994
David Gold

Glaxo Holdings received FDA approval to provide its anti-HIV nucleoside analog 3TC (also called lamivudine) to adults and children who have CD4 counts of less than 300. Eligible individuals must have failed or be intolerant to approved anti-HIV therapies. They also must be unable to qualify for ongoing clinical trials. Physicians may call 800/248-9757 for enrollment information.

In March, the parent company of Burroughs Wellcome Co. (the manufacturer of such drugs as AZT and acyclovir) acquired an option to develop and market 3TC. The drug is presently in phase II/III trials involving over 800 patients in North America and Europe. According to Glaxo, 3TC has been well- tolerated and has helped patients gain weight and energy. An application for FDA approval for the drug is expected in the fall of 1994. 3TC also has shown activity against Hepatitis B (HBV) in test tube experiments and is in Phase II trials for chronic HBV.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

9405
GM080306

Copyright © 1994 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .